Fernando Franco Pérez1, Javier Lavernia2, David Aguiar-Bujanda3, José Miramón4, Josep Gumá5, Rut Álvarez6, José Gómez-Codina7, Francisco García Arroyo8, Marta Llanos9, Miguel Marin10, Jesus Alfaro11, Cristina Quero12, Mayte Delgado13, Esteban Nogales14, Francisco Menarguez15, Natividad Martinez15, Maria Torrente16, Ana Royuela17, Delvys Abreu18, Mariano Provencio16. 1. Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain. Electronic address: f3franc@gmail.com. 2. Department of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain. 3. Department of Medical Oncology, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canarias, Spain. 4. Department of Medical Oncology, Hospital Serranía de Ronda, Málaga, Spain. 5. Department of Medical Oncology, Hospital Universitari Sant Joan de Reus, Reus, Spain. 6. Department of Medical Oncology, Hospital Universitario Virgen de la Salud, Toledo, Spain. 7. Department of Medical Oncology, Hospital Universitari i Politècnic La Fe, Valencia, Spain. 8. Department of Medical Oncology, Complejo Hospitalario de Pontevedra, Pontevedra, Spain. 9. Department of Medical Oncology, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain. 10. Department of Medical Oncology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain. 11. Department of Medical Oncology, Instituto Oncológico de Kutxa, Donistia, Spain. 12. Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain. 13. Department of Medical Oncology, Hospital Universitario San Cecilio, Granada, Spain. 14. Department of Medical Oncology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain. 15. Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain. 16. Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain. 17. Department of Biostatistics, Hospital Universitario Puerta de Hierro, Majadahonda, Spain. 18. Department of Medical Oncology, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canarias, Spain.
Abstract
INTRODUCTION: Primary breast lymphoma is a rare form of localized extranodal lymphoma, which affects the mammary glands unilaterally or bilaterally, and can also affect the regional lymph nodes. MATERIALS AND METHODS: We reviewed 55 patients, with disease stages IE and IIE, diagnosed in 16 Spanish institutions between 1989 and 2016. A serial of clinical variables and treatment were collected, and overall survival (OS) and progression-free survival (PFS) were calculated. RESULTS: Of the 55 patients, 96.4% were women with an average age of 69 years. A total of 53 patients corresponded to non-Hodgkin lymphoma (NHL), of whom 36.3% had lymph node involvement upon diagnosis. Of the patients, 58.2% were stage IE, and 41.8% were stage IIE. Treatments received included radiotherapy (36.3%), chemotherapy (85.5%), and rituximab (in 38 of the 45 patients with NHL treated with chemotherapy). In all, 82.2% of complete responses were achieved. OS and progression-free survival at 5 years in NHL patients was 76% and 73%, respectively. CONCLUSION: Current treatments (chemotherapy, immunotherapy, and radiotherapy) achieve good control of the disease, with an OS of 5 years in 80% of the patients, although there is no consensus in treatment, given the scarce incidence of these lymphomas.
INTRODUCTION:Primary breast lymphoma is a rare form of localized extranodal lymphoma, which affects the mammary glands unilaterally or bilaterally, and can also affect the regional lymph nodes. MATERIALS AND METHODS: We reviewed 55 patients, with disease stages IE and IIE, diagnosed in 16 Spanish institutions between 1989 and 2016. A serial of clinical variables and treatment were collected, and overall survival (OS) and progression-free survival (PFS) were calculated. RESULTS: Of the 55 patients, 96.4% were women with an average age of 69 years. A total of 53 patients corresponded to non-Hodgkin lymphoma (NHL), of whom 36.3% had lymph node involvement upon diagnosis. Of the patients, 58.2% were stage IE, and 41.8% were stage IIE. Treatments received included radiotherapy (36.3%), chemotherapy (85.5%), and rituximab (in 38 of the 45 patients with NHL treated with chemotherapy). In all, 82.2% of complete responses were achieved. OS and progression-free survival at 5 years in NHLpatients was 76% and 73%, respectively. CONCLUSION: Current treatments (chemotherapy, immunotherapy, and radiotherapy) achieve good control of the disease, with an OS of 5 years in 80% of the patients, although there is no consensus in treatment, given the scarce incidence of these lymphomas.
Authors: Mario Faenza; Andrea Ronchi; Antonio Santoriello; Corrado Rubino; Gorizio Pieretti; Antonio Guastafierro; Giuseppe Andrea Ferraro; Giovanni Francesco Nicoletti Journal: Int J Surg Case Rep Date: 2017-07-21
Authors: Fernando Franco; Julia González-Rincón; Javier Lavernia; Juan F García; Paloma Martín; Carmen Bellas; Miguel A Piris; Lucia Pedrosa; José Miramón; José Gómez-Codina; Delvys Rodríguez-Abreu; Isidro Machado; Carmen Illueca; Jesús Alfaro; Mariano Provencio; Margarita Sánchez-Beato Journal: Oncotarget Date: 2017-10-24
Authors: Eleanor C Ory; Desu Chen; Kristi R Chakrabarti; Peipei Zhang; James I Andorko; Christopher M Jewell; Wolfgang Losert; Stuart S Martin Journal: Oncotarget Date: 2017-12-04